Blog
Page 34
Li Lu Is Betting Big on These Stocks in 2026Li Lu’s Himalaya Capital Management reported a $3.23 billion equity portfolio in the latest quarter, revealing a characteristically focused collection of high-conviction positio…
VALUE: After Hours (S08 E03): Ian Cassel on MicroCapClub, the PlanetMicroCap acquisition and IntelligentCMDuring their recent episode, Taylor, Carlisle, and Ian Cassel discussed: Why Even Elite Investors Are Only Right Half the Time Letting Winners Run: The Difference Between 20% Ga…
Taiwan Semiconductor Manufacturing Company Limited (TSM): Our Calculation of Intrinsic ValueEach week we run a DCF (Discounted Cash Flow) model on a company from our watchlist. This week’s pick: Taiwan Semiconductor Manufacturing Company Limited (TSM) Profile Taiwan Se…
Weekly Investing Roundup – News, Podcasts, Interviews (01/30/2026)This week’s best investing news: Fireside Chat with Howard Marks of Oaktree Capital Management (Pepperdine) Jeremy Grantham – Part 1 VALUING AI Extreme Bubble, New Golden Era, o…
Cricut, Inc. (CRCT): Deep Value Consumer Hardware/Software EcosystemAs part of our ongoing series at The Acquirer’s Multiple, we highlight stocks from our Stock Screeners that may represent mispriced opportunities relative to their underlying ca…
VALUE: After Hours (S08 E02): Healthcare Spending as a Share of GDP: U.S. vs. the WorldDuring their recent episode, Taylor, Carlisle, and Andrew Summers discussed Is Healthcare Spending as a Share of GDP: U.S. vs. the World. Here’s an excerpt from the episode: And…
Chuck Akre: Quality Compounding Through Trim DisciplineChuck Akre’s latest 13F reveals a portfolio that continues to embody his long-standing investment philosophy: own a concentrated basket of durable compounders, let management te…- VALUE: After Hours (S08 E02): GLP-1 Drugs as a ‘Magic Pill’: Obesity, Heart, Cognitive BenefitsDuring their recent episode, Taylor, Carlisle, and Andrew Summers discussed GLP-1 Drugs as a ‘Magic Pill’: Obesity, Heart, Cognitive Benefits. Here’s an excerpt from the episode…
Howard Marks: Never Confuse Brains In A Bull MarketHoward Marks often reminds investors that success comes not from clairvoyance but from discipline, psychology, and price. During a Pepperdine fireside chat, he reiterated that “…
This Week’s Deep-Value Landscape: Acquirer’s Multiple Large-Cap ScreenThis week’s Acquirer’s Multiple® Large-Cap screen again clusters around capital-intensive cyclicals, cheap financials, and mature hardware franchises whose realized cash economi…- VALUE: After Hours (S08 E02): 2026–2030 Patent Cliff: Biggest in Pharma HistoryDuring their recent episode, Taylor, Carlisle, and Andrew Summers discussed 2026–2030 Patent Cliff: Biggest in Pharma History. Here’s an excerpt from the episode: Now, the one t…
Cliff Asness: Do The Rational Strategy and Keep RepeatingCliff Asness has spent decades navigating the emotional and statistical terrain of markets, and this interview highlights how much of the game hinges on behavior. As he put it, …
Top Superinvestors Are Buying Tyson Foods (TSN)According to the latest 13F filings, several respected value and quantitative managers increased their exposure to Tyson Foods (TSN) last quarter. The activity reflects improvin…- VALUE: After Hours (S08 E02): Healthcare Investing ExplainedDuring their recent episode, Taylor, Carlisle, and Andrew Summers discussed Healthcare Investing Explained. Here’s an excerpt from the episode: Andrew: Sure. So, I’ve spent the …
David Einhorn: The U.S Equity Market Is The Most Expensive We’ve Seen Since We Began Managing MoneyGreenlight Capital closed out 2025 with a year that showcased both the strength of macro positioning and the challenges of traditional long-short equity investing. The firm note…
Prem Watsa: Positioning Through Deep Value & OptionalityThe latest 13F from Fairfax Financial reflects a steady, high-conviction allocation toward real assets, energy, and restructuring platforms — with minimal turnover during the qu…- VALUE: After Hours (S08 E02): Andrew Summers of Summers Value Partners on healthcare, biotech $GILD, $QURE and $ELMDDuring their recent episode, Taylor, Carlisle, and Andrew Summers discussed: Healthcare Investing Explained 2026–2030 Patent Cliff: Biggest in Pharma History GLP-1 Drugs as a “M…
Wingstop (WING): Our Calculation of Intrinsic ValueEach week we run a DCF (Discounted Cash Flow) model on a company from our watchlist. This week’s pick: Wingstop Inc. (WING). Profile Wingstop is a fast-growing global quick-serv…